2 news items
KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth
KRMD
1 May 24
of the leadership
KORU Medical Systems Signs a Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for a Novel Subcutaneous Immunoglobulin
KRMD
6 Mar 24
and AISs, and continuing leadership in large volume subcutaneous infusion. Actual results may differ materially from these statements due to potential
- Prev
- 1
- Next